4/5/2011

Royalty Pharma said it has bought certain royalty rights for Lexiscan, a radionuclide myocardial perfusion imaging agent. The drug was developed by CV Therapeutics, now owned by Gilead, and Astellas Pharma.

Full Story:
MarketWire

Related Summaries